Compare Eaton Corporation plc (ETN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Recursion Pharmaceuticals Inc — how do they compare? Eaton Corporation plc trades at $403.54 (market cap $160.31B), while Recursion Pharmaceuticals Inc trades at $3.16 (market cap $1.75B). The key difference: Eaton Corporation plc is far larger — about 91.6× Recursion Pharmaceuticals Inc's market cap, and Eaton Corporation plc pays a 1.07% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ETN | RXRX | |
|---|---|---|
Market Cap | $160.31B | $1.75B |
Sector | Technology | Health |
52-Week High | $435.78 | $6.79 |
52-Week Low | $315.82 | $2.84 |
Enterprise Value | $181.40B | $1.17B |
Dividend Yield | 1.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $404.20, down 2.72% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.81 exceeding expectations. Analyst consensus is overwhelmingly positive with 25 buy ratings and a $449.50 price target. Recent news highlights growth in AI data center power infrastructure and a new sustainability report showing 40% emissions reduction.
ETN's outlook remains favorable due to robust demand in data center and aerospace markets, though elevated valuation multiples (P/E 40.4) pose a risk if growth moderates. The stock offers upside to consensus targets but faces execution risks from large 2026 investing outflows. Dividend payments provide income support with the next $1.10 distribution scheduled for May 29, 2026.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
